Literature DB >> 22175654

Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study.

Cynthia M Carlsson1, Guofan Xu, Zhifei Wen, Jodi H Barnet, Hanna M Blazel, Richard J Chappell, James H Stein, Sanjay Asthana, Mark A Sager, David C Alsop, Howard A Rowley, Sean B Fain, Sterling C Johnson.   

Abstract

BACKGROUND/AIMS: Hypercholesterolemia in midlife increases risk for Alzheimer's disease (AD) and contributes to cerebrovascular dysregulation - an early finding in preclinical AD pathology. Statins improve vascular reactivity, but it is unknown if they increase regional cerebral blood flow (CBF) in individuals at risk for AD.
METHODS: In a randomized, controlled, double-blind pilot study, 16 asymptomatic middle-aged adults with parental history of AD were randomized to atorvastatin or placebo daily for 4 months. At baseline and month 4, regional CBF was measured using arterial spin-labeling magnetic resonance imaging and endothelial function was measured using brachial artery ultrasound.
RESULTS: At baseline, participants with low HDL-cholesterol, higher global vascular risk, and greater endothelial dysfunction had reduced regional CBF in areas of the brain related to memory and learning (all p < 0.03). Using voxel-based analysis, 4 months of atorvastatin increased CBF in bilateral hippocampi, fusiform gyrus, putamen and insular cortices compared to placebo.
CONCLUSION: In this pilot study, atorvastatin increased regional CBF in persons at risk for AD. Further research is warranted to confirm whether statins increase CBF in areas of the brain related to memory and learning and whether such perfusion changes are associated with a delay in the onset of AD. CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov Identifier: NCT00751907.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22175654      PMCID: PMC3576818          DOI: 10.2174/156720512803251075

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  35 in total

1.  Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

Authors:  K Fassbender; M Simons; C Bergmann; M Stroick; D Lutjohann; P Keller; H Runz; S Kuhl; T Bertsch; K von Bergmann; M Hennerici; K Beyreuther; T Hartmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

Review 2.  Pleiotropic effects of HMG-CoA reductase inhibitors.

Authors:  Nikos Werner; Georg Nickenig; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2002-03       Impact factor: 17.165

3.  Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial.

Authors:  Mikael Simons; Frank Schwärzler; Dieter Lütjohann; Klaus von Bergmann; Konrad Beyreuther; Johannes Dichgans; Henning Wormstall; Tobias Hartmann; Jörg B Schulz
Journal:  Ann Neurol       Date:  2002-09       Impact factor: 10.422

4.  Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention.

Authors:  Mark A Sager; Bruce Hermann; Asenath La Rue
Journal:  J Geriatr Psychiatry Neurol       Date:  2005-12       Impact factor: 2.680

5.  Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment.

Authors:  M Yamada; Z Huang; T Dalkara; M Endres; U Laufs; C Waeber; P L Huang; J K Liao; M A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  2000-04       Impact factor: 6.200

6.  Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease.

Authors:  P Sterzer; F Meintzschel; A Rösler; H Lanfermann; H Steinmetz; M Sitzer
Journal:  Stroke       Date:  2001-12-01       Impact factor: 7.914

7.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

8.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

Authors:  B Wolozin; W Kellman; P Ruosseau; G G Celesia; G Siegel
Journal:  Arch Neurol       Date:  2000-10

9.  Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.

Authors:  S Amin-Hanjani; N E Stagliano; M Yamada; P L Huang; J K Liao; M A Moskowitz
Journal:  Stroke       Date:  2001-04       Impact factor: 7.914

10.  Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease.

Authors:  Miia Kivipelto; Eeva-Liisa Helkala; Mikko P Laakso; Tuomo Hänninen; Merja Hallikainen; Kari Alhainen; Susan Iivonen; Arto Mannermaa; Jaakko Tuomilehto; Aulikki Nissinen; Hilkka Soininen
Journal:  Ann Intern Med       Date:  2002-08-06       Impact factor: 25.391

View more
  11 in total

1.  Detrimental effect of systemic vascular risk factors on brain hemodynamic function assessed with MRI.

Authors:  Kevin S King; Min Sheng; Peiying Liu; Christopher D Maroules; Craig D Rubin; Ron M Peshock; Roderick W McColl; Hanzhang Lu
Journal:  Neuroradiol J       Date:  2018-01-10

2.  Cortical pattern of reduced perfusion in hearing loss revealed by ASL-MRI.

Authors:  Sara Ponticorvo; Renzo Manara; Josef Pfeuffer; Arianna Cappiello; Sofia Cuoco; Maria Teresa Pellecchia; Renato Saponiero; Donato Troisi; Claudia Cassandro; Marta John; Alfonso Scarpa; Ettore Cassandro; Francesco Di Salle; Fabrizio Esposito
Journal:  Hum Brain Mapp       Date:  2019-02-04       Impact factor: 5.038

3.  Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).

Authors:  Walter J Lukiw
Journal:  Expert Opin Emerg Drugs       Date:  2012-03-23       Impact factor: 4.191

Review 4.  Statins, cognition, and dementia—systematic review and methodological commentary.

Authors:  Melinda C Power; Jennifer Weuve; A Richey Sharrett; Deborah Blacker; Rebecca F Gottesman
Journal:  Nat Rev Neurol       Date:  2015-03-24       Impact factor: 42.937

5.  Statin contribution to middle cerebral artery blood flow velocity in older adults at risk for dementia.

Authors:  Stacey E Aaron; Tsubasa Tomoto; Rong Zhang; John P Thyfault; Eric D Vidoni; Robert N Montgomery; Jeffrey M Burns; Sandra A Billinger
Journal:  Eur J Appl Physiol       Date:  2022-08-12       Impact factor: 3.346

Review 6.  The role of cholesterol metabolism in Alzheimer's disease.

Authors:  Jia-Hao Sun; Jin-Tai Yu; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-18       Impact factor: 5.590

7.  Association of Cardiovascular and Alzheimer's Disease Risk Factors with Intracranial Arterial Blood Flow in Whites and African Americans.

Authors:  Lindsay R Clark; Derek Norton; Sara E Berman; Sterling C Johnson; Barbara B Bendlin; Oliver Wieben; Patrick Turski; Cynthia Carlsson; Sanjay Asthana; Carey E Gleason; Heather M Johnson
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

8.  Low cerebral blood flow is associated with lower memory function in metabolic syndrome.

Authors:  Alex C Birdsill; Cynthia M Carlsson; Auriel A Willette; Ozioma C Okonkwo; Sterling C Johnson; Guofan Xu; Jennifer M Oh; Catherine L Gallagher; Rebecca L Koscik; Erin M Jonaitis; Bruce P Hermann; Asenath LaRue; Howard A Rowley; Sanjay Asthana; Mark A Sager; Barbara B Bendlin
Journal:  Obesity (Silver Spring)       Date:  2013-05-19       Impact factor: 5.002

9.  Physical activity, cognitive function, and brain health: what is the role of exercise training in the prevention of dementia?

Authors:  Sara M Gregory; Beth Parker; Paul D Thompson
Journal:  Brain Sci       Date:  2012-11-29

Review 10.  Effects of Plasma Lipids and Statins on Cognitive Function.

Authors:  Rui Li; Tian-Jun Wang; Pei-Yuan Lyu; Yang Liu; Wei-Hong Chen; Ming-Yue Fan; Jing Xu
Journal:  Chin Med J (Engl)       Date:  2018-02-20       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.